Menu
Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.
Price
Target price
€119.84

€119.84

0.860%
1.02
0.860%
€136.82
 
09.05.24 / Tradegate WKN: A0D9T1 / Symbol: DXCM / Name: DexCom / Stock / Healthcare Equipment & Supplies / Large Cap /
Please give a prediction to see the opinions of the community
sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.
Your prediction

Financial data and news for DexCom

sharewise wants to provide you with the best news and tools for DexCom, so we directly link to the best financial data sources.

News

DexCom (DXCM) Q1 2024 Earnings Call Transcript: https://g.foolcdn.com/editorial/images/1/featured-transcript-logo-template-2023-01-12.jpg
DexCom (DXCM) Q1 2024 Earnings Call Transcript

Image source: The Motley Fool.

DexCom (NASDAQ: DXCM)Q1 2024 Earnings CallApr 25, 2024, 4:30 p.m. ET

Operator

Continue reading

Source Fool.com

2 Growth Stocks to Buy Hand Over Fist in April: https://g.foolcdn.com/editorial/images/771856/physician-shaking-patients-hand.jpg
2 Growth Stocks to Buy Hand Over Fist in April

Earnings season, which is fast approaching, is often somewhat volatile for the stock market. Companies that overdeliver or fail to deliver can see their share prices move significantly overnight.

2 Medical Device Stocks to Buy Hand Over Fist in March: https://g.foolcdn.com/editorial/images/768037/medical-professional-smiling.jpg
2 Medical Device Stocks to Buy Hand Over Fist in March

A good way to invest in the healthcare industry's continued growth is by targeting businesses that make medical devices. Such equipment aids physicians in surgery, helps patients recover, and can

Stelo by Dexcom First Glucose Biosensor to be Cleared by FDA as Over-the-Counter: https://mms.businesswire.com/media/20240305044213/en/2055849/5/Stelo_Pickleball.jpg
Stelo by Dexcom First Glucose Biosensor to be Cleared by FDA as Over-the-Counter


DexCom, Inc. (NASDAQ:DXCM), the global leader in real-time continuous glucose monitoring for people with diabetes, announced today that the FDA has cleared Stelo by Dexcom – the first glucose

Dexcom Showcases Leadership in AID and Power of Dexcom CGM in Type 2 Diabetes With New Data at ATTD
Dexcom Showcases Leadership in AID and Power of Dexcom CGM in Type 2 Diabetes With New Data at ATTD


DexCom, Inc. (NASDAQ: DXCM), the global leader in real-time continuous glucose monitoring (CGM) for people with diabetes, announced compelling new clinical evidence supporting the use of Dexcom

DexCom (DXCM) Q4 2023 Earnings Call Transcript: https://g.foolcdn.com/editorial/images/1/featured-transcript-logo-template-2023-01-12.jpg
DexCom (DXCM) Q4 2023 Earnings Call Transcript

Image source: The Motley Fool.

DexCom (NASDAQ: DXCM)Q4 2023 Earnings CallFeb 08, 2024, 4:30 p.m. ET

Operator

Continue reading

Source Fool.com

Prediction: 2 Stocks That Could Trounce the Market: https://g.foolcdn.com/editorial/images/763717/physician-shaking-patients-hand.jpg
Prediction: 2 Stocks That Could Trounce the Market

Every investor wants to beat the market, but doing so is notoriously difficult. That's why many settle for matching the performance of some prominent index by buying the appropriate exchange-traded

Dexcom G7, the Smallest, Most Accurate, Easy-to-Use CGM Now Connects to the Tandem t:slim X2 Insulin Pump: https://mms.businesswire.com/media/20231206143334/en/1959997/5/Dexcom_G7_Tandem_tslim_X2.jpg
Dexcom G7, the Smallest, Most Accurate, Easy-to-Use CGM Now Connects to the Tandem t:slim X2 Insulin Pump


DexCom, Inc. (Nasdaq: DXCM), the global leader in real-time continuous glucose monitoring for people with diabetes, announced today the Dexcom G7 Continuous Glucose Monitoring (CGM) System now

Ozempic Might Be Helping Abbott Laboratories and DexCom Stock. Here's How.: https://g.foolcdn.com/editorial/images/755494/investor-talks-with-group-of-medical-professionals.jpg
Ozempic Might Be Helping Abbott Laboratories and DexCom Stock. Here's How.

Novo Nordisk's (NYSE: NVO) Ozempic is indicated to treat diabetes, and its wild success and household name is making a few cardiometabolic device companies rather nervous. With a powerful tool to

2 Stock Split Growth Stocks to Buy and Hold: https://g.foolcdn.com/editorial/images/755119/a-person-working-on-a-laptop.jpg
2 Stock Split Growth Stocks to Buy and Hold

Last year, tech giant Amazon (NASDAQ: AMZN) and medical device specialist DexCom (NASDAQ: DXCM) were among the several high-profile companies to conduct stock splits. This move attracted plenty of

Is DexCom the Next Big Growth Stock?: https://g.foolcdn.com/editorial/images/755210/investor-sitting-at-computer-with-pen.jpg
Is DexCom the Next Big Growth Stock?

With shares of DexCom (NASDAQ: DXCM) falling 11% this year amid a steadily rising market, one might think that the medical device maker's growth potential is ebbing compared to its former glory. But

Could DexCom Stock Help You Become a Millionaire?: https://g.foolcdn.com/editorial/images/754788/two-couples-on-a-yacht.jpg
Could DexCom Stock Help You Become a Millionaire?

Getting to $1 million is a great long-term goal for investors to target. Not only could that be a good nest egg to tap into during retirement, but you could also use that money to invest in dividend

Dexcom Unveils Portrait Gallery to Portray Emotional Highs and Lows of Living With Diabetes on World Diabetes Day: https://mms.businesswire.com/media/20231113585613/en/1943712/5/Dexcom-NDAM-16-9-v4.jpg
Dexcom Unveils Portrait Gallery to Portray Emotional Highs and Lows of Living With Diabetes on World Diabetes Day


DexCom, Inc. (NASDAQ: DXCM), the global leader in real-time continuous glucose monitoring (CGM) systems for people with diabetes, is teaming up with Dexcom Warriors from around the globe to help

Dexcom Reports First Quarter 2024 Financial Results: https://mms.businesswire.com/media/20191106005764/en/685171/5/Dexcom_Registered_no_bug.jpg
Dexcom Reports First Quarter 2024 Financial Results


DexCom, Inc. (Nasdaq: DXCM) today reported its financial results as of and for the quarter ended March 31, 2024.



First Quarter 2024 Financial Highlights:




  • Revenue grew 24% year-over-year to

Dexcom Publishes Annual Sustainability Report: https://mms.businesswire.com/media/20191106005764/en/685171/5/Dexcom_Registered_no_bug.jpg
Dexcom Publishes Annual Sustainability Report


DexCom, Inc. (NASDAQ:DXCM), the leader in real-time continuous glucose monitoring (CGM) for people with diabetes, today released its annual Sustainability Report. This report provides updates on

Dexcom Schedules First Quarter 2024 Earnings Release and Conference Call for April 25, 2024 at 4:30 p.m. Eastern Time: https://mms.businesswire.com/media/20191106005764/en/685171/5/Dexcom_Registered_no_bug.jpg
Dexcom Schedules First Quarter 2024 Earnings Release and Conference Call for April 25, 2024 at 4:30 p.m. Eastern Time


DexCom, Inc. (NASDAQ:DXCM) today announced that it plans to release its first quarter 2024 financial results after market close on Thursday, April 25, 2024. Management will hold a conference call

Dexcom Announces Upcoming Conference Presentation: https://mms.businesswire.com/media/20191106005764/en/685171/5/Dexcom_Registered_no_bug.jpg
Dexcom Announces Upcoming Conference Presentation


DexCom, Inc. (NASDAQ:DXCM) today announced that Sean Christensen, Vice President, Finance and Investor Relations, will present an update on the company at the 45th Annual Raymond James

Dexcom Reports Fourth Quarter and Fiscal Year 2023 Financial Results: https://mms.businesswire.com/media/20191106005764/en/685171/5/Dexcom_Registered_no_bug.jpg
Dexcom Reports Fourth Quarter and Fiscal Year 2023 Financial Results


DexCom, Inc. (Nasdaq: DXCM) today reported its financial results as of and for the quarter and fiscal year ended December 31, 2023.



Fourth Quarter 2023 Financial Highlights:




  • Revenue grew 27%

Dexcom Schedules Fourth Quarter and Fiscal Year 2023 Earnings Release and Conference Call for February 8, 2024 at 4:30 p.m. Eastern Time: https://mms.businesswire.com/media/20191106005764/en/685171/5/Dexcom_Registered_no_bug.jpg
Dexcom Schedules Fourth Quarter and Fiscal Year 2023 Earnings Release and Conference Call for February 8, 2024 at 4:30 p.m. Eastern Time


DexCom, Inc. (NASDAQ:DXCM) today announced that it plans to release its fourth quarter and fiscal year 2023 financial results after market close on Thursday, February 8, 2024. Management will hold

Dexcom Secures Future in Europe, Middle East, and Africa by Breaking Ground on New Manufacturing Facility in Ireland: https://mms.businesswire.com/media/20191106005764/en/685171/5/Dexcom_Registered_no_bug.jpg
Dexcom Secures Future in Europe, Middle East, and Africa by Breaking Ground on New Manufacturing Facility in Ireland


DexCom, Inc. (Nasdaq: DXCM), a global leader in real-time continuous glucose monitoring (rtCGM) for people with diabetes, has officially broken ground on its new state-of-the-art manufacturing

A Powerful Alliance: Dexcom G7 Now Connects to Tandem t:slim X2: https://mms.businesswire.com/media/20191106005764/en/685171/5/Dexcom_Registered_no_bug.jpg
A Powerful Alliance: Dexcom G7 Now Connects to Tandem t:slim X2


DexCom, Inc. (Nasdaq: DXCM), a global leader in real-time continuous glucose monitoring for people with diabetes, announced today the Dexcom G7 Continuous Glucose Monitoring (CGM) System now

Dexcom Reports Preliminary, Unaudited Revenue for the Fourth Quarter and Fiscal Year 2023 and Initial 2024 Outlook: https://mms.businesswire.com/media/20191106005764/en/685171/5/Dexcom_Registered_no_bug.jpg
Dexcom Reports Preliminary, Unaudited Revenue for the Fourth Quarter and Fiscal Year 2023 and Initial 2024 Outlook


DexCom, Inc. (Nasdaq: DXCM), the leader in real-time continuous glucose monitoring (“CGM”), today reported that it expects preliminary, unaudited revenue for the fourth quarter ended December 31

Dexcom to Present at 42nd Annual J.P. Morgan Healthcare Conference: https://mms.businesswire.com/media/20191106005764/en/685171/5/Dexcom_Registered_no_bug.jpg
Dexcom to Present at 42nd Annual J.P. Morgan Healthcare Conference


DexCom, Inc. (NASDAQ:DXCM) today announced that Kevin Sayer, Chairman, President and Chief Executive Officer, will present an update on the company at the 42nd annual J.P. Morgan Healthcare

Dexcom Announces Upcoming Conference Presentation: https://mms.businesswire.com/media/20191106005764/en/685171/5/Dexcom_Registered_no_bug.jpg
Dexcom Announces Upcoming Conference Presentation


DexCom, Inc. (NASDAQ:DXCM) today announced that Jereme Sylvain, Executive Vice President and Chief Financial Officer, will present an update on the company at the Piper Sandler 35th Annual

DexCom Stock Gains from GLP-1 Diabetic Users: https://www.marketbeat.com/logos/articles/med_20240331131923_chart-dxcm.jpg
DexCom Stock Gains from GLP-1 Diabetic Users

DexCom Inc. (NASDAQ: DXCM) is a leading medical device company in the medical sector that specializes in continuous glucose monitoring (CGM) systems. People with diabetes use CGM systems to